Global Longlife Hospital and Research Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: October 11, 2025, 2:12 am

Competitors of Global Longlife Hospital and Research Ltd

All Competitor Stocks of Global Longlife Hospital and Research Ltd

Quarterly Result

Last Updated: May 31, 2025, 5:54 am

Below is a detailed analysis of the quarterly data for Global Longlife Hospital and Research Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.58 Cr. (Sep 2024) to 0.00 Cr., marking a decrease of 0.58 Cr..
• For Expenses, as of Mar 2025, the value is 0.35 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.39 Cr. (Sep 2024) to 0.35 Cr., marking a decrease of 4.04 Cr..
• For Operating Profit, as of Mar 2025, the value is -0.35 Cr.. The value appears strong and on an upward trend. It has increased from -3.81 Cr. (Sep 2024) to -0.35 Cr., marking an increase of 3.46 Cr..
• For OPM %, as of Mar 2025, the value is 0.00%. The value appears strong and on an upward trend. It has increased from -656.90% (Sep 2024) to 0.00%, marking an increase of 656.90%.
• For Other Income, as of Mar 2025, the value is -0.67 Cr.. The value appears to be declining and may need further review. It has decreased from 5.69 Cr. (Sep 2024) to -0.67 Cr., marking a decrease of 6.36 Cr..
• For Interest, as of Mar 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.28 Cr. (Sep 2024) to 0.00 Cr., marking a decrease of 0.28 Cr..
• For Depreciation, as of Mar 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.48 Cr. (Sep 2024) to 0.00 Cr., marking a decrease of 0.48 Cr..
• For Profit before tax, as of Mar 2025, the value is -1.02 Cr.. The value appears to be declining and may need further review. It has decreased from 1.12 Cr. (Sep 2024) to -1.02 Cr., marking a decrease of 2.14 Cr..
• For Tax %, as of Mar 2025, the value is 2.94%. The value appears to be increasing, which may not be favorable. It has increased from -11.61% (Sep 2024) to 2.94%, marking an increase of 14.55%.
• For Net Profit, as of Mar 2025, the value is -1.04 Cr.. The value appears to be declining and may need further review. It has decreased from 1.24 Cr. (Sep 2024) to -1.04 Cr., marking a decrease of 2.28 Cr..
• For EPS in Rs, as of Mar 2025, the value is -0.99. The value appears to be declining and may need further review. It has decreased from 1.18 (Sep 2024) to -0.99, marking a decrease of 2.17.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: August 23, 2025, 1:02 pm

Growth

Last Updated: September 5, 2025, 3:36 pm

Balance Sheet

Last Updated: August 11, 2025, 4:04 pm

Below is a detailed analysis of the balance sheet data for Global Longlife Hospital and Research Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 10.50 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 10.50 Cr..
• For Reserves, as of Mar 2025, the value is 16.29 Cr.. The value appears strong and on an upward trend. It has increased from 15.43 Cr. (Mar 2024) to 16.29 Cr., marking an increase of 0.86 Cr..
• For Borrowings, as of Mar 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 12.74 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 12.74 Cr..
• For Other Liabilities, as of Mar 2025, the value is 0.06 Cr.. The value appears to be improving (decreasing). It has decreased from 3.07 Cr. (Mar 2024) to 0.06 Cr., marking a decrease of 3.01 Cr..
• For Total Liabilities, as of Mar 2025, the value is 26.85 Cr.. The value appears to be improving (decreasing). It has decreased from 41.74 Cr. (Mar 2024) to 26.85 Cr., marking a decrease of 14.89 Cr..
• For Fixed Assets, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 17.27 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 17.27 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Investments, as of Mar 2025, the value is 0.03 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.03 Cr..
• For Other Assets, as of Mar 2025, the value is 26.82 Cr.. The value appears strong and on an upward trend. It has increased from 24.44 Cr. (Mar 2024) to 26.82 Cr., marking an increase of 2.38 Cr..
• For Total Assets, as of Mar 2025, the value is 26.85 Cr.. The value appears to be declining and may need further review. It has decreased from 41.74 Cr. (Mar 2024) to 26.85 Cr., marking a decrease of 14.89 Cr..

Notably, the Reserves (16.29 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Global Longlife Hospital and Research Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 5. It has increased from -2.08 (Mar 24) to 0.19, marking an increase of 2.27.
• For Diluted EPS (Rs.), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 5. It has increased from -2.08 (Mar 24) to 0.19, marking an increase of 2.27.
• For Cash EPS (Rs.), as of Mar 25, the value is 0.64. This value is below the healthy minimum of 3. It has increased from -0.89 (Mar 24) to 0.64, marking an increase of 1.53.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 25.51. It has increased from 24.70 (Mar 24) to 25.51, marking an increase of 0.81.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 25.51. It has increased from 24.70 (Mar 24) to 25.51, marking an increase of 0.81.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.54. It has decreased from 12.87 (Mar 24) to 0.54, marking a decrease of 12.33.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 0.81. This value is below the healthy minimum of 2. It has increased from -0.23 (Mar 24) to 0.81, marking an increase of 1.04.
• For PBIT / Share (Rs.), as of Mar 25, the value is 0.35. This value is within the healthy range. It has increased from -1.43 (Mar 24) to 0.35, marking an increase of 1.78.
• For PBT / Share (Rs.), as of Mar 25, the value is 0.09. This value is within the healthy range. It has increased from -2.16 (Mar 24) to 0.09, marking an increase of 2.25.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 0.18. This value is below the healthy minimum of 2. It has increased from -2.08 (Mar 24) to 0.18, marking an increase of 2.26.
• For PBDIT Margin (%), as of Mar 25, the value is 148.50. This value is within the healthy range. It has increased from -1.83 (Mar 24) to 148.50, marking an increase of 150.33.
• For PBIT Margin (%), as of Mar 25, the value is 65.02. This value exceeds the healthy maximum of 20. It has increased from -11.08 (Mar 24) to 65.02, marking an increase of 76.10.
• For PBT Margin (%), as of Mar 25, the value is 17.18. This value is within the healthy range. It has increased from -16.76 (Mar 24) to 17.18, marking an increase of 33.94.
• For Net Profit Margin (%), as of Mar 25, the value is 34.41. This value exceeds the healthy maximum of 10. It has increased from -16.19 (Mar 24) to 34.41, marking an increase of 50.60.
• For Return on Networth / Equity (%), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 15. It has increased from -8.43 (Mar 24) to 0.74, marking an increase of 9.17.
• For Return on Capital Employeed (%), as of Mar 25, the value is 1.39. This value is below the healthy minimum of 10. It has increased from -5.09 (Mar 24) to 1.39, marking an increase of 6.48.
• For Return On Assets (%), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 5. It has increased from -5.24 (Mar 24) to 0.74, marking an increase of 5.98.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.13 (Mar 24) to 0.00, marking a decrease of 0.13.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.49 (Mar 24) to 0.00, marking a decrease of 0.49.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.01. It has decreased from 0.22 (Mar 24) to 0.01, marking a decrease of 0.21.
• For Current Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1.5. It has decreased from 0.31 (Mar 24) to 0.00, marking a decrease of 0.31.
• For Quick Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. It has decreased from 0.28 (Mar 24) to 0.00, marking a decrease of 0.28.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 8.36. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 8.36, marking an increase of 8.36.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 3.10. This value is within the healthy range. It has increased from -0.32 (Mar 24) to 3.10, marking an increase of 3.42.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.72. This value is below the healthy minimum of 3. It has increased from -1.85 (Mar 24) to 1.72, marking an increase of 3.57.
• For Enterprise Value (Cr.), as of Mar 25, the value is -1.58. It has decreased from 53.35 (Mar 24) to -1.58, marking a decrease of 54.93.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is -2.74. This value is below the healthy minimum of 1. It has decreased from 3.95 (Mar 24) to -2.74, marking a decrease of 6.69.
• For EV / EBITDA (X), as of Mar 25, the value is -1.85. This value is below the healthy minimum of 5. It has increased from -215.57 (Mar 24) to -1.85, marking an increase of 213.72.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 34.48. This value exceeds the healthy maximum of 3. It has increased from 3.03 (Mar 24) to 34.48, marking an increase of 31.45.
• For Price / BV (X), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 1. It has decreased from 1.58 (Mar 24) to 0.74, marking a decrease of 0.84.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 34.54. This value exceeds the healthy maximum of 3. It has increased from 3.03 (Mar 24) to 34.54, marking an increase of 31.51.
• For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has increased from -0.05 (Mar 24) to 0.01, marking an increase of 0.06.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness